Stocks · News reference

Cogent Biosciences To Present Preclinical Data From Its Novel JAK2 V617F Mutant-Selective Inhibitor At The 2026 European Hematology Association Congress, June 11-14

Jun 12, 2026, 12:03 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 2, 2026, 8:27 PMBenzinga Newsdesk
Cogent Biosciences Enters Commercial Supply Agreement With Hovione On Sept 1, 2026; To Purchase Minimum Percentages Of Bezuclastinib Products From Hovione; Agreement Effective For Five-Year Term With Automatic Two-Year Renewals
On September 1, 2026, Cogent Biosciences, Inc. (the "Company") entered into a Commercial Supply Agreement (the "Agreement") with Hovione FarmaCiencia S.A. ("Hovione") to manufacture bezuclastinib
COGT
SEC EDGARSep 2, 2026, 8:11 PMSEC EDGAR
8-K filing — Cogent Biosciences, Inc. (COGT)
Filed: 2026-09-02 AccNo: 0001193125-26-380194 Size: 138 KB Item 1.01: Entry into a Material Definitive Agreement
COGT
BenzingaAug 17, 2026, 4:08 PMBenzinga Newsdesk
Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55
Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $52 to $55.
COGT
BenzingaAug 12, 2026, 12:33 PMBenzinga Newsdesk
Guggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $52
Guggenheim analyst Michael Schmidt maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $45 to $52.
COGT